MedWatch

Novo Nordisk remains coy over Wegovy blockbuster potential

Sales of Novo Nordisk’s newest obesity treatment, Wegovy, have been steadily increasing since its summer launch. Despite this, Novo CEO Lars Fruergaard Jørgensen remains silent on the drug’s blockbuster potential.

Lars Fruergaard Jørgensen, CEO of Novo Nordisk | Photo: Stine Bidstrup/ERH

With last Friday’s release of Novo Nordisk’s quarterly report for 2021, the pharmaceutical firm chose to reveal the actual sales figures for obesity drug Wegovy for the first time.

According to these numbers, sales of the treatment have gradually increased since it was launched in June last year. In the first three months of the year, Wegovy passed the DKK 1bn (USD 141.5m) milestone, generating DKK 1.4bn (USD 198.1m) in sales.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs